Patents by Inventor Felix Vega

Felix Vega has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210330896
    Abstract: A device for performing injections in a patient includes a syringe holder with a needle guard, a cannula extending from the syringe holder, a needle slidably disposed over the cannula, and a slider on the syringe holder. The cannula has a blunt tip and a cannula length, and the needle has a sharp tip and a needle length that is shorter than the cannula length. The slider is coupled with the needle and is configured to slide the needle along the cannula from an extended position, in which the sharp tip of the needle is located at or immediately adjacent the blunt tip of the cannula, to a retracted position, in which the sharp tip is housed within the needle guard of the syringe holder.
    Type: Application
    Filed: April 27, 2021
    Publication date: October 28, 2021
    Applicant: Arya Medical, Inc.
    Inventors: John P. FEZZA, Felix VEGA, Darrin James KENT, David James PRINCE
  • Patent number: 9114172
    Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: August 25, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
  • Patent number: 8962025
    Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: February 24, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
  • Publication number: 20140120078
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Application
    Filed: December 9, 2013
    Publication date: May 1, 2014
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
  • Publication number: 20140086898
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Application
    Filed: August 19, 2013
    Publication date: March 27, 2014
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian
  • Patent number: 8603511
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: December 10, 2013
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
  • Patent number: 8512729
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: August 20, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
  • Patent number: 8357378
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: January 22, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
  • Patent number: 8303981
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: November 6, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
  • Publication number: 20120207813
    Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.
    Type: Application
    Filed: April 26, 2012
    Publication date: August 16, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Woonza M. RHEE, Cary J. REICH, A. Edward OSAWA, Felix VEGA
  • Publication number: 20120134980
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Application
    Filed: July 1, 2011
    Publication date: May 31, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
  • Publication number: 20110223231
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Application
    Filed: May 24, 2011
    Publication date: September 15, 2011
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
  • Patent number: 7871637
    Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: January 18, 2011
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich, Donald G. Wallace, Narinder S. Shargill, Felix Vega
  • Publication number: 20080187591
    Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.
    Type: Application
    Filed: August 1, 2007
    Publication date: August 7, 2008
    Applicants: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
  • Publication number: 20080169856
    Abstract: The present invention provides a current impulse generator that is fed by a high voltage source. The high voltage from the source creates an electric field which turns into a corona current by means of a corona current source. The corona current source charges a floating electrode with electrostatic energy which is rapidly discharged by means of a discharge switch into a spherical electrode producing a current impulse. The spherical electrode transmits the current impulse to an antenna which emits an electromagnetic wideband energy beam which actuates on electric triggers from a distance.
    Type: Application
    Filed: August 3, 2007
    Publication date: July 17, 2008
    Inventors: Francisco Jose Roman C., Jose Felix Vega S.
  • Publication number: 20080085316
    Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
    Type: Application
    Filed: September 21, 2007
    Publication date: April 10, 2008
    Applicant: Baxter Healthcare Corporation
    Inventors: Zhen Qian, A. Osawa, Cary Reich, Donald Wallace, Narinder Shargill, Felix Vega
  • Publication number: 20040162578
    Abstract: A percutaneous tissue track closure assembly (2) includes a semipermeable barrier (26) mounted to the distal end of a tubular barrier carrier (20). The barrier is passed down a tissue track (12) and into a blood vessel (18) where the barrier is expanded to close off the blood vessel opening (14). A syringe device is used to drive a hemostatic flowable material (30) through a delivery tube (34) and into the tissue track. The semipermeable barrier permits blood to flow therethrough but prevents passage of the hemostatic flowable material therethrough. The hemostatic material includes a material which swells upon contact with blood, and a blood clotting agent. After an appropriate period of time, the barrier is collapsed and the barrier carrier and delivery tube are removed from the tissue track.
    Type: Application
    Filed: February 10, 2004
    Publication date: August 19, 2004
    Applicant: Fusion Medical Technologies, Inc.
    Inventors: Russell J. Redmond, Claude A. Vidal, Cary J. Reich, Felix Vega
  • Patent number: 6699262
    Abstract: A percutaneous tissue track closure assembly (2) includes a semipermeable barrier (26) mounted to the distal end of a tubular barrier carrier (20). The barrier is passed down a tissue track (12) and into a blood vessel (18) where the barrier is expanded to close off the blood vessel opening (14). A syringe device is used to drive a hemostatic flowable material (30) through a delivery tube (34) and into the tissue track. The semipermeable barrier permits blood to flow therethrough but prevents passage of the hemostatic flowable material therethrough. The hemostatic material includes a material which swells upon contact with blood, and a blood clotting agent. After an appropriate period of time, the barrier is collapsed and the barrier carrier and delivery tube are removed from the tissue track.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: March 2, 2004
    Assignee: Fusion Medical Technologies, Inc.
    Inventors: Russell J. Redmond, Claude A. Vidal, Cary J. Reich, Felix Vega
  • Patent number: 6613070
    Abstract: Systems and method for sealing vascular penetrations rely on placement of a temporary barrier on the posterior side of the penetration. Penetrations are then sealed by delivering a hemostatic gel to a region over the penetration, where the barrier both inhibits loss of the gel and promotes back flow of blood into the gel. A combination of natural clotting factors in the blood and hemostatic agents in the gel promote rapid and effective sealing of the vascular penetration. Specific systems for performing the method include a barrier carrier for temporary placement of the barrier within the blood vessel and a gel delivery tube which may be positioned within a tissue tract or line of penetration simultaneously with the barrier carrier to deliver the hemostatic gel.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: September 2, 2003
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Russell J. Redmond, Claude Vidal, Cary J. Reich, Felix Vega, Michael Collinson, Joseph F. Rondinone
  • Publication number: 20020193448
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Application
    Filed: April 21, 2000
    Publication date: December 19, 2002
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa